Purple biotech presents positive interim phase 1b study results for cm24 at the american association of cancer research 2022 annual meeting

First-in-class monoclonal antibody in combination with opdivo® (nivolumab) demonstrates strong safety and an initial efficacy profile for pdac

PPBT Ratings Summary

PPBT Quant Ranking